OKX Wallet Now Integrated with Morpheus
SINGAPORE, July 31, 2024 /PRNewswire/ — OKX, a global Web3 technology company, has issued updates for July 31, 2024. OKX Wallet Now Integrated with Morpheus... Read more.
OKX Wallet Now Integrated with SuperBridge for Seamless Blockchain Rollup Interactions
SINGAPORE, July 30, 2024 /PRNewswire/ — OKX, a global Web3 technology company, has issued updates for July 31, 2024. OKX Wallet Now Integrated with SuperBridge... Read more.
OKX Ventures Hosts X Spaces on the Future of BTCFi
SINGAPORE, July 30, 2024 /PRNewswire/ — OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, has issued updates for... Read more.
OKX Wallet Users Can Now Earn Immutable’s Gems via Web Extension
SINGAPORE, July 30, 2024 /PRNewswire/ — OKX, a global Web3 technology company, has issued updates for July 30, 2024. OKX Wallet Users Can Now Earn Immutable’s... Read more.
TE Connectivity announces pricing of $350 million 4.625% senior notes offering
SCHAFFHAUSEN, Switzerland, July 30, 2024 /PRNewswire/ — TE Connectivity Ltd. (NYSE: TEL) (“TE Connectivity”) today announced that its wholly-owned... Read more.
GRUPO IDESA, S.A. DE C.V. ANNOUNCES EXPIRATION AND EXPIRATION DATE RESULTS OF ITS CASH TENDER OFFER
MEXICO CITY, July 30, 2024 /PRNewswire/ — Grupo IDESA, S.A. de C.V. (the “Company“) announces the expiration and expiration date results of the... Read more.
RECONAFRICA ENTERS INTO DEFINITIVE STRATEGIC FARM DOWN AGREEMENT WITH BW ENERGY
CALGARY, AB, July 30, 2024 /PRNewswire/ – Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF)... Read more.
Appian Will Seek to Reinstate Judgment Against Pegasystems, Inc. In Virginia Supreme Court
In its opinion, the Court of Appeals of Virginia fundamentally misread and misapplied precedent from the Supreme Court of Virginia and failed to give due regard... Read more.
FDA Grants Orphan Drug Designation (ODD) Status to Zymedi’s ZMA001 for Pulmonary Arterial Hypertension
INCHEON, South Korea, July 30, 2024 /PRNewswire/ — Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development... Read more.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or death New regimen... Read more.